August 4, 2009 – Watson Pharmaceuticals Inc. said this week it received FDA approval on its abbreviated new drug applications (ANDAs) for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths, which are the generic equivalent to AstraZeneca's Toprol XL tablets.
Metoprolol succinate extended-release is a beta-blocker used to treat angina, heart failure and high blood pressure. Watson intends to launch the product immediately.
Toprol XL 25 mg and 50 mg and its generic equivalents had annual sales of approximately $628 million for the 12 months ending June 2009, according to IMS sales data.
For more information: www.watson.com